Dr. Forde is an expert in treating lung cancer, mesothelioma, and other thoracic cancers. He received his training in internal medicine and oncology in Ireland before going on to complete a fellowship at Johns Hopkins. He currently serves as Co-Director of the Division of Upper Aerodigestive Malignancies in the Department of Oncology at Johns Hopkins and leads the Thoracic Oncology Clinical Research Program.

His research focuses on the immuno-oncology of upper aerodigestive malignancies, specifically the role of immunotherapy in treating mesothelioma and lung cancer. His work has resulted in the development of several ongoing phase 3 clinical trials. In 2022, his research, published in the New England Journal of Medicine, led to the FDA approval of neoadjuvant chemo-immunotherapy for the treatment of surgically operable lung cancer.

Dr. Forde is also the principal investigator for the thoracic cancer immunobiology biospecimen repository protocol at Johns Hopkins. He is committed to providing top-notch, compassionate care for his patients with the support of a team of oncology specialists, nurse practitioners, and dedicated staff. Dr. Forde holds the title of Co-Director of Division of Upper Aerodigestive Malignancies, Director of Thoracic Oncology Clinical Research Program, Associate Professor of Oncology. He is affiliated with Oncology - Upper Aerodigestive Cancer, Lung Cancer Program and Sidney Kimmel Comprehensive Cancer Center.

He earned his degrees of MBBCh; Royal College of Surgeons in Ireland (2004) and completed his Residencies in Medical Oncology at Beaumont Hospital (2009), Medical Oncology at Mater Misericordiae University Hospital (2008) and Internal Medicine at Royal College of Physicians Ireland (2007) and Fellowships at Medical Oncology at Cork University Hospital (2010), Oncology at Johns Hopkins University School of Medicine (2014), Medical Oncology at St James's Hospital (2011). He also completed additional training in Johns Hopkins Leadership Development Program 2020-21.